Vaccine development against Neisseria meningitidis

Related Experiment Video

Updated: Jun 5, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Ulrich Vogel1, Heike Claus

  • 1University of Würzburg, Institute for Hygiene and Microbiology, Reference Laboratory for Meningococci, Germany. uvogel@hygiene.uni-wuerzburg.de

Microbial Biotechnology
|January 25, 2011
PubMed

Insights

Developing effective meningococcal vaccines, especially for serogroup B, remains challenging due to bacterial immune evasion. Current research explores novel approaches like outer membrane vesicles and protein-based strategies to combat this serious communicable disease.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Meningococcal disease presents high fatality rates, particularly in infants and adolescents.
  • Bacterial immune evasion strategies, such as molecular mimicry, hinder vaccine development.
  • Existing polysaccharide vaccines are ineffective against serogroup B, a significant global health concern.

Purpose of the Study:

  • To review the challenges and advancements in developing vaccines against Neisseria meningitidis, focusing on serogroup B.
  • To highlight the limitations of current vaccines and the need for broader protection.
  • To discuss emerging research directions for novel meningococcal vaccines.

Main Methods:

  • Review of existing literature on meningococcal disease and vaccine development.
  • Analysis of bacterial immune evasion mechanisms.
  • Exploration of recent genomic and biochemical approaches for identifying immunogenic targets.
  • Discussion of ongoing research into novel vaccine candidates.

Main Results:

  • Protein-conjugated and non-conjugated polysaccharide vaccines target serogroups A, C, W-135, and Y but not B.
  • Detoxified outer membrane vesicles are used for serogroup B protection, but new targets are sought.
  • Genome mining and biochemical studies have identified promising conserved outer membrane proteins.
  • Subcapsular proteins may not provide complete protection against all serogroup B variants.

Conclusions:

  • Vaccine development for meningococcal disease, especially serogroup B, requires overcoming bacterial immune evasion.
  • Novel strategies involving outer membrane proteins, modified polysaccharides, and mimotopes are under investigation.
  • Further research using surrogate assays and molecular epidemiology is crucial for evaluating new protein-based vaccines.

More Related Videos

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection05:55

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Related Concept Videos

Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...